I joined AstraZenenca in April 2017 as an Early Phase Medical Oncologist. Previously I spent 12 years as a practising clinician at The University of Manchester and The Christie NHS Foundation Trust where I was medical lead for the Experimental Cancer Medicine Team.
My interest is in first-in-human, first-in-class and Phase 1 clinical trials of novel agents. As Director Physician in Early Phase Oncology, I lead the clinical development of a range of experimental therapies. I review clinical data from the Phase I/II trials and provide input on the strategic direction of the programme.
At AstraZeneca we have an exciting portfolio of pipeline drugs, particularly in the DNA Damage Response arena. This offers me a unique opportunity to contribute to scientifically driven combination trials and comparative studies to aid investment decisions.
My biggest motivation is giving patients the opportunity to access exciting new therapies to treat cancer. At AstraZeneca, I can do this by interacting with investigators across the world and have the privilege of working with an exceptional team of colleagues. Together, our drive and ambition allow me to make a difference on a scale much greater than that I could hope to achieve in academia.
At AstraZeneca there is a passion to drive forward through the science but with a patient-centric focus. This is important when planning a clinical trial and also when a study is recruiting, achieved by forging great relationships with investigators to ensure proactive and collaborative dialogue.
The training at AstraZeneca gives clinicians an unparalleled technical understanding of drug-development processes that is rarely available in clinical academia. AstraZeneca offers an environment in which physicians who are intelligent, inquisitive and with a passion to learn can thrive. As an integral part of my professional role, I am able to maintain my clinical practice through one clinical session per week as part of my professional charitable activities.
At AstraZeneca I have the privilege of working with an exceptional team whose drive and ambition allow me to make a difference on a much greater scale.
The training at AstraZeneca gives clinicians a technical understanding of drug-development decisions and processes that is rarely available in clinical academia.
2016 National Researcher of the Year
The Christie Research and Education Awards
2014 Experimental Cancer Medicine Team
Leading cancer care, The Christie Staff Awards
2013 ESMO Award
Contribution to the ESMO Fellowship Programme
2017 the first recipient of the Diploma in Experimental Therapeutics from the Faculty of Pharmaceutical Medicine
2016 Invited speaker at the European Society for Medical Oncology conference
2016 Successful application to Cancer Research UK to support an investigator-initiated commercial Phase Ib trial
Phase I dose-finding and pharmacokinetic study or eribulin-liposomal formulation in patients with solid tumours
Evans TR, Dean E, Molife R, Lopez J, Ranson M, El-Khouly F, Ishtiaq Zubain I, Savulsky C, Reydeman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.
Published Online, British Journal of Cancer, 25JAN19
First-in-human Phase 1/2 Study of Tisotumab Vedotin in Advanced and/or Metastatic Solid Tumours.
De Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J-P, Arkenau H-T, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sorensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U.
Accepted in The Lancet Oncology 2018 In Press
Pharmacokinetic Effects and Safety of Olaparib in Combination with Endocrine Therapy (Tamoxifen, Anastrazole or Letrozole): A Phase I Study in Patients with Advanced Solid Tumours
Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer, J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.
Accepted in Advances in Therapy 2018 In Press
Novel Early Phase Clinical Trial Design in Oncology
O.Brien C, Carter L, Cook N, Dean E.
Pharmaceutical Medicine October 2017, Volume 31, Issue 5, pp297-307
AKT inhibition in solid tumours with AKT1 mutation
Hyman DM, Smyth L, Donoghue M, Westin S, Bedard P, Dean E, Bando , El-Khoueiry A, Pérez-Fidalgo J, Mita A, Schellens J, Chang M, Reichel J, Bouvier N, Selcuklu S, Soumerai T, Torrisi J, Erinerji J, Ambrose H, Barrett C, Dougherty B, Foxley A, Lindemann J, McEwen R, Pass M, Shiavon G, Berger M, Chandarlapaty S, Solit D, Banerji U, Baselga J, Taylor B.
JCO In Press, Accepted Mar2017
A Phase I pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumours.
Soria J, Gan H, Blagden S, Plummer R, Arkenau H, Ranson Malcolm R, Evans T, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean EJ, Brwon J, Gibson D, Peddareddiagari V, Murray S, Nebot N, Mazumdar, J, Swartz L, Auger K, Fleming R, Singh R, Millward M.
Annals of Oncology. Published Online 11 October 2016.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R.
European Journal of Cancer Vol 68, Nov2016, Pgs 1-10.
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014.
*Dean E, *Basu B, , Puglisi M, Greystroke A, Ong M, Burke WM, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson MR, Banerji U.
Clin Cancer Res. 2015 Mar 24. pii: clincanres.2422.2014. *Equal contribution